Safety and Efficacy of Evobrutinib in Relapsing MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
Lancet Neurol 2024 Sep 19;[EPub Ahead of Print], X Montalban, P Vermersch, DL Arnold, A Bar-Or, BAC Cree, AH Cross, E Kubala Havrdova, L Kappos, O Stuve, H Wiendl, JS Wolinsky, F Dahlke, C Le Bolay, L Shen Loo, S Gopalakrishnan, Y Hyvert, A Javor, H Guehring, N Tenenbaum, D TomicFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.